Abstract：Objective To explore the clinical effect and safety of SOX regimen (Oxaliplatin combined with Teggio) in the treatment of advanced triple negative breast cancer, so as to provide a reference for clinicians to choose rational drug regimen. Methods A total of 102 patients with advanced triple negative breast cancer admitted to Zhongyi Northeast International Hospital from January 1, 2017 to December 31, 2019 were selected as the research objects, and they were divided into the control group and the experimental group according to random number table method, with 51 cases in each group. The experimental group was treated with SOX regimen, while the control group was treated with TP regimen (Oxaliplatin combined with Docetaxel). The total effective rate, total incidence of adverse reactions, serum carbohydrate antigen 153 (CA153) and cancer embryo antigen (CEA) levels were compared between the two groups. Results The total effective rate of the experimental group was higher than that of the control group, and the difference was statistically significant (P＜0.05). The total incidence of adverse reactions in the experimental group was lower than that in the control group, and the difference was statistically significant (P＜0.05). After treatment, the serum CA153 and CEA levels in two groups were lower than those before treatment, and the serum CA153 and CEA levels in experimental group were lower than those in control group, the differences were statistically significant (P＜0.05). Conclusion In the treatment of advanced triple negative breast cancer, SOX regimen has significant clinical effect and higher safety,which is worthy of promotion and application in future clinical work.
路颖. SOX方案治疗晚期三阴性乳腺癌的临床效果及安全性[J]. 中国当代医药, 2021, 28(12): 105-107转111.
LU Ying. Clinical effect and safety of SOX regimen in the treatment of advanced triple negative breast cancer. 中国当代医药, 2021, 28(12): 105-107转111.
京公网安备 11010502046607号